Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.
| Autor: | van Heeswijk RP; Janssen Infectious Diseases BVBA, Beerse, Belgium rvheesw1@its.jnj.com., Dannemann B; Janssen Research & Development, LLC, Titusville, NJ, USA., Hoetelmans RM; Janssen Infectious Diseases BVBA, Beerse, Belgium. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2014 Sep; Vol. 69 (9), pp. 2310-8. Date of Electronic Publication: 2014 May 23. |
| DOI: | 10.1093/jac/dku171 |
| Abstrakt: | Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in healthy subjects and patients with drug-susceptible or multidrug-resistant TB have assessed the pharmacokinetics and drug-drug interaction profile of bedaquiline. Potential interactions have been assessed between bedaquiline and first- and second-line anti-TB drugs (rifampicin, rifapentine, isoniazid, pyrazinamide, ethambutol, kanamycin, ofloxacin and cycloserine), commonly used antiretroviral agents (lopinavir/ritonavir, nevirapine and efavirenz) and a potent CYP3A inhibitor (ketoconazole). This review summarizes the pharmacokinetic profile of bedaquiline as well as the results of the drug-drug interaction studies. (© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|